α-Synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells: an

enteroendocrine cells free fatty acid receptors microbiome short-chain fatty acids toll-like receptors

Journal

Brain communications
ISSN: 2632-1297
Titre abrégé: Brain Commun
Pays: England
ID NLM: 101755125

Informations de publication

Date de publication:
2023
Historique:
received: 19 04 2023
revised: 03 09 2023
accepted: 23 10 2023
medline: 13 11 2023
pubmed: 13 11 2023
entrez: 13 11 2023
Statut: epublish

Résumé

Caudo-rostral migration of pathological forms of α-synuclein from the gut to the brain is proposed as an early feature in Parkinson's disease pathogenesis, but the underlying mechanisms remain unknown. Intestinal epithelial enteroendocrine cells sense and respond to numerous luminal signals, including bacterial factors, and transmit this information to the brain via the enteric nervous system and vagus nerve. There is evidence that gut bacteria composition and their metabolites change in Parkinson's disease patients, and these alterations can trigger α-synuclein pathology in animal models of the disorder. Here, we investigated the effect of toll-like receptor and free fatty acid receptor agonists on the intracellular level of α-synuclein and its release using mouse secretin tumour cell line 1 enteroendocrine cells. Secretin tumour cell line 1 enteroendocrine cells were treated for 24 or 48 h with toll-like receptor agonists (toll-like receptor 4 selective lipopolysaccharide; toll-like receptor 2 selective Pam3CysSerLys4) and the free fatty acid receptor 2/3 agonists butyrate, propionate and acetate. The effect of selective receptor antagonists on the agonists' effects after 24 hours was also investigated. The level of α-synuclein protein was measured in cell lysates and cell culture media by western blot and enzyme-linked immunosorbent assay. The level of α-synuclein and tumour necrosis factor messenger RNA was measured by quantitative reverse transcription real-time polymerase chain reaction. Stimulation of secretin tumour cell line 1 enteroendocrine cells for 24 and 48 hours with toll-like receptor and free fatty acid receptor agonists significantly increased the amount of intracellular α-synuclein and the release of α-synuclein from the cells into the culture medium. Both effects were significantly reduced by antagonists selective for each receptor. Toll-like receptor and free fatty acid receptor agonists also significantly increased tumour necrosis factor transcription, and this was effectively inhibited by corresponding antagonists. Elevated intracellular α-synuclein increases the likelihood of aggregation and conversion to toxic forms. Factors derived from bacteria induce α-synuclein accumulation in secretin tumour cell line 1 enteroendocrine cells. Here, we provide support for a mechanism by which exposure of enteroendocrine cells to specific bacterial factors found in Parkinson's disease gut dysbiosis might facilitate accumulation of α-synuclein pathology in the gut.

Identifiants

pubmed: 37953845
doi: 10.1093/braincomms/fcad285
pii: fcad285
pmc: PMC10636561
doi:

Types de publication

Journal Article

Langues

eng

Pagination

fcad285

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.

Déclaration de conflit d'intérêts

The authors report no competing interests or relevant disclosures.

Références

Acta Neuropathol. 2017 Feb;133(2):303-319
pubmed: 27888296
Diabetes. 2012 Feb;61(2):364-71
pubmed: 22190648
Proc Natl Acad Sci U S A. 2015 Apr 28;112(17):5455-60
pubmed: 25870276
Neurosci Lett. 2006 Mar 20;396(1):67-72
pubmed: 16330147
Nature. 1997 Aug 28;388(6645):839-40
pubmed: 9278044
Exp Cell Res. 2020 Feb 1;387(1):111772
pubmed: 31836471
Neurology. 2009 Nov 24;73(21):1752-8
pubmed: 19933976
Brain. 2013 Jul;136(Pt 7):2077-97
pubmed: 23771339
Mov Disord. 2015 Mar;30(3):350-8
pubmed: 25476529
Science. 1999 Jul 30;285(5428):736-9
pubmed: 10426996
NPJ Parkinsons Dis. 2017 Jan 11;3:3
pubmed: 28649603
Brain. 2020 Oct 1;143(10):3077-3088
pubmed: 32830221
Nat Commun. 2013;4:1562
pubmed: 23463005
Nat Rev Gastroenterol Hepatol. 2018 Dec;15(12):765-784
pubmed: 30069036
Lancet Neurol. 2020 Feb;19(2):179-194
pubmed: 31753762
J Neuroinflammation. 2022 Jun 6;19(1):135
pubmed: 35668422
Ann Med. 2021 Dec;53(1):611-625
pubmed: 33860738
Brain Behav Immun. 2018 May;70:48-60
pubmed: 29471030
Science. 2003 Oct 31;302(5646):841
pubmed: 14593171
Eur J Histochem. 2021 Nov 02;65(4):
pubmed: 34726359
Parkinsonism Relat Disord. 2016 Nov;32:66-72
pubmed: 27591074
NPJ Parkinsons Dis. 2020 Jun 12;6:11
pubmed: 32566740
Microbiol Mol Biol Rev. 2016 Aug 10;80(3):891-903
pubmed: 27512100
Am J Physiol Gastrointest Liver Physiol. 2007 Jun;292(6):G1770-83
pubmed: 17395901
Front Aging Neurosci. 2023 Jan 25;15:1099018
pubmed: 36761177
Biochim Biophys Acta Proteins Proteom. 2019 Jul - Aug;1867(7-8):701-709
pubmed: 31096048
Nat Rev Neurosci. 2017 Jul;18(7):435-450
pubmed: 28592904
J Clin Invest. 2015 Feb;125(2):782-6
pubmed: 25555217
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
pubmed: 12498954
Mov Disord. 2019 Mar;34(3):396-405
pubmed: 30576008
J Mol Med (Berl). 2017 Jan;95(1):13-20
pubmed: 27639584
Sci Rep. 2020 Jan 20;10(1):694
pubmed: 31959927
Int Immunol. 2008 Aug;20(8):961-70
pubmed: 18544573
Mol Chem Neuropathol. 1991 Jun;14(3):153-97
pubmed: 1958262
JCI Insight. 2017 Jun 15;2(12):
pubmed: 28614796
Brain Res. 2018 Aug 15;1693(Pt B):201-206
pubmed: 29360467
Lancet. 2015 Aug 29;386(9996):896-912
pubmed: 25904081
Nat Protoc. 2014 Sep;9(9):2135-46
pubmed: 25122523
J Immunol. 2007 Apr 1;178(7):4296-303
pubmed: 17371986
Science. 2018 Sep 21;361(6408):
pubmed: 30237325
Cell. 2016 Dec 1;167(6):1469-1480.e12
pubmed: 27912057
J Physiol. 2011 Mar 1;589(Pt 5):1081-93
pubmed: 21224236
Parkinsonism Relat Disord. 2022 Jan;94:1-9
pubmed: 34844021
Gut. 2019 May;68(5):829-843
pubmed: 30554160
Am J Pathol. 2003 Nov;163(5):2093-101
pubmed: 14578207
Mov Disord. 2013 Aug;28(9):1241-9
pubmed: 23712625
Front Microbiol. 2020 Sep 18;11:582582
pubmed: 33042100
Endocrinology. 2013 Oct;154(10):3552-64
pubmed: 23885020
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Brain Behav Immun Health. 2020 Mar 18;4:100060
pubmed: 34589845
Mol Pharmacol. 2014 Aug;86(2):200-10
pubmed: 24870406
Cell Rep. 2015 Oct 27;13(4):771-782
pubmed: 26489461
NPJ Parkinsons Dis. 2022 Oct 10;8(1):129
pubmed: 36216843
CNS Neurosci Ther. 2022 Nov;28(11):1675-1688
pubmed: 35822696
Nature. 2019 Jul;571(7766):565-569
pubmed: 31316206
Proc Natl Acad Sci U S A. 2011 May 10;108(19):8030-5
pubmed: 21518883
J Biol Chem. 2016 Jan 1;291(1):303-17
pubmed: 26518871

Auteurs

Michael J Hurley (MJ)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London NW3 2PF, UK.
Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD 20815, USA.

Elisa Menozzi (E)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London NW3 2PF, UK.
Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD 20815, USA.

Sofia Koletsi (S)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London NW3 2PF, UK.
Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD 20815, USA.

Rachel Bates (R)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London NW3 2PF, UK.
Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD 20815, USA.

Matthew E Gegg (ME)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London NW3 2PF, UK.
Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD 20815, USA.

Kai-Yin Chau (KY)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London NW3 2PF, UK.
Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD 20815, USA.

Hervé M Blottière (HM)

Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD 20815, USA.
Université Paris-Saclay, INRAE, MetaGenoPolis, Jouy en Josas, & Nantes Université, INRAE, UMR 1280 PhAN, Nantes 44093, France.

Jane Macnaughtan (J)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London NW3 2PF, UK.
Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD 20815, USA.
Institute for Liver and Digestive Health, University College London, London NW3 2PF, UK.

Anthony H V Schapira (AHV)

Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London NW3 2PF, UK.
Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD 20815, USA.

Classifications MeSH